The Endocannabinoid System & PTSD
Every human has an endocannabinoid system — a network of receptors, endogenous ligands, and metabolic enzymes that regulates mood, memory, pain, appetite, and stress response. Research suggests this system may function differently in people with PTSD. The biology provides plausible rationale for why veterans might seek cannabis; whether that plausibility translates to clinical efficacy is a separate question.
Biology vs. Clinical Efficacy
The endocannabinoid system is demonstrably altered in PTSD (Neumeister 2013). Fear extinction — the brain mechanism behind trauma therapy — requires endocannabinoid signaling (Marsicano 2002). But FAAH inhibition to boost anandamide did not improve PTSD in a 2025 RCT. Mechanism does not equal medicine.
The Basic Components
The endocannabinoid system consists of:
- Receptors: CB1 (primarily in the brain, peripheral nervous system, and some organs) and CB2 (primarily in immune tissues)
- Endocannabinoids: Anandamide (N-arachidonoylethanolamide, AEA) and 2-arachidonoylglycerol (2-AG) — the endogenous ligands
- Metabolic enzymes: Fatty acid amide hydrolase (FAAH) degrades anandamide; monoacylglycerol lipase (MAGL) degrades 2-AG
The system was discovered in the late 1980s and early 1990s, with Raphael Mechoulam's lab identifying anandamide in 1992. It is now understood to be one of the major neuromodulatory systems of the brain, comparable in importance to the dopaminergic, serotonergic, and glutamatergic systems.
What THC and CBD Do to This System
- THC is a partial agonist at CB1 and CB2 receptors — meaning it activates these receptors the same way anandamide does, but with higher potency and longer duration. This produces the classic cannabis "high," appetite stimulation, analgesia, and anxiolysis (or anxiogenesis, depending on dose).
- CBD has complex pharmacology. It is a weak antagonist at CB1/CB2, a positive allosteric modulator of CB1, an agonist at serotonin 5-HT1A and TRPV1 receptors, and an inhibitor of FAAH (increasing anandamide). CBD is non-intoxicating at typical doses.
Neumeister 2013 — The PET Imaging Study
This landmark PET imaging study used a radiotracer for CB1 receptors to examine the brains of 60 participants (25 with PTSD). Key findings:
- 19.5% higher brain CB1 receptor availability in PTSD patients
- 53–58% lower anandamide levels in PTSD patients
- Together, these three biomarkers (CB1 availability, anandamide level, and peripheral FAAH activity) correctly classified approximately 85% of PTSD cases
The interpretation: PTSD appears to involve endocannabinoid system deficiency. Lower anandamide drives upregulation of CB1 receptors (the brain's compensatory response). This is consistent with what might be called "clinical endocannabinoid deficiency" — a pattern some researchers have hypothesized for several conditions including fibromyalgia, migraine, and IBS.
Marsicano 2002 — Fear Extinction Requires Cannabinoid Signaling
Marsicano's lab demonstrated that mice lacking CB1 receptors (CB1 knockouts) were unable to extinguish learned fear responses. This is a profound finding: fear extinction — the brain's mechanism for learning that a previously threatening cue is now safe — fundamentally depends on endocannabinoid signaling. Extinction is the mechanism behind the most effective PTSD psychotherapies (prolonged exposure, cognitive processing therapy).
This provides compelling biological rationale for why cannabis might help PTSD — supporting endocannabinoid signaling could theoretically enhance extinction learning. It also raises the opposite possibility: high-dose THC could interfere with endocannabinoid homeostasis and impair extinction (see Bedard-Gilligan 2022 finding on the PTSD page).
The FAAH Inhibitor Disappointment
The cleanest way to test the endocannabinoid hypothesis is to raise anandamide levels directly without introducing exogenous THC. This can be done with FAAH inhibitors — drugs that block the enzyme that degrades anandamide, allowing endogenous anandamide to accumulate.
A 2025 RCT of 100 PTSD patients tested PF-04457845, a potent FAAH inhibitor, versus placebo. Anandamide levels rose as expected. PTSD outcomes did not improve. This is a strong test of the endocannabinoid deficiency hypothesis: if raising anandamide were therapeutic for PTSD, this trial should have detected it. It did not.
The negative FAAH result does not invalidate the endocannabinoid system's role in PTSD biology, but it does complicate the clinical translation. It is possible that the temporal dynamics of endocannabinoid signaling matter more than bulk levels, that specific brain regions need targeted signaling, or that anandamide alone is insufficient and 2-AG is also needed. It is also possible that endocannabinoid dysregulation in PTSD is a consequence rather than a cause of the disorder.
What This Means for Cannabis as Treatment
Biology and clinical efficacy are not the same question. You can have a strong mechanistic rationale and still find that the intervention does not help in real patients. This is one of the hardest lessons of modern drug development:
- Mechanism exists: The endocannabinoid system is altered in PTSD, and cannabinoids interact with this system
- Plausibility exists: Supporting endocannabinoid signaling could theoretically help PTSD
- Efficacy is not demonstrated: The only completed RCT of smoked cannabis in veterans showed no advantage over placebo; the FAAH inhibitor RCT also showed no effect
- What this suggests: Raw activation of the endocannabinoid system is probably not sufficient to treat PTSD. Whatever is therapeutic (if anything) requires more targeted mechanisms than current interventions provide.
Clinical Endocannabinoid Deficiency Hypothesis
Ethan Russo has proposed the "clinical endocannabinoid deficiency" hypothesis, suggesting that certain conditions (fibromyalgia, migraine, IBS, and possibly PTSD) share a common pattern of low baseline endocannabinoid tone. Supporting evidence includes the PTSD PET data above, the Squire 2024 Gulf War Illness findings (see GWI page), and clinical observations that patients with these conditions often report subjective benefit from cannabis. The hypothesis is controversial and has not been definitively proven — but it motivates much of the ongoing research in this area.